GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (LTS:0M26) » Definitions » Quality Rank

XOMA (LTS:0M26) Quality Rank


View and export this data going back to 2018. Start your Free Trial

What is XOMA Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

XOMA Quality Rank Related Terms

Thank you for viewing the detailed overview of XOMA's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA (LTS:0M26) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (LTS:0M26) » Definitions » Quality Rank
Comparable Companies
MRSN PSTX XERS AGEN INO MGNX EPIX RVNC INZY CRMD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA X0M1:Germany
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
Website
https://www.xoma.com
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.